NEW YORK, MONTREAL, and SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ - ICBS Ltd., (OTCPK: ICBT), board of directors, announced that the company will focus its efforts on the pharmaceutical market through its subsidiary, Canadian Bio Med Systems Ltd., and the environmental market through its partnership with BioSpec Global Solutions Inc., of Quebec.
High Interest in a New Approach
"We feel that at this point, we should concentrate on the most promising investments and that is with Canadian Bio Med Systems and BioSpec Global Solutions. We have therefore decided to cease offering business consulting services through our subsidiary, Inter Canadian Business Services along with divesting our interest in Ramapo Valley Brewery" said Dr. George Tsoukas, Chairman.
ICBS has positioned itself with 51% ownership in Canadian Bio Med Systems and 25% interest in BioSpec Global Solutions.
These companies have entered a multi billion dollar market place in recession proof industries.
ICBS will continue to acquire undervalued opportunities in these selective high-growth industries to create value for our shareholders and target partners by combining expertise in both the product and capital markets. Taking interest in companies to align with their long-term interest and help build enduring value for our investors.
Canadian Bio Med Systems, has acquired the licensing rights to two new potentially revolutionary drugs in the billion dollar ophthalmic arena. The drug for the treatment of Glaucoma is being developed by Daniel Stamer, PhD and Ronald Heimark, PhD at the
BioSpec Global Solutions has developed state-of-the-art technologies for rapid, onsite (remote) monitoring of microbial contamination in drinking water, recreational water, agriculture food production, pharmaceuticals and medical applications. TOGS(TM) 9000 instrument is a single test, precision, portable incubator utilizing the patented technology provide on-site testing of microbial contamination in drinking water. Used in conjunction with a chromogenic reagent, it provides an accurate, virtually fool-proof microbial test for field, rural and remote applications in the detection of Total Coliforms and E.coli to WHO standards using globally approved methods (USEPA, AWWA-APHA). The company holds world wide patents
NB. This news release includes statements that constitute forward-looking statements. Please be aware that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may vary materially from those in the forward-looking statements as a result of any number of factors, including the risk factors contained in the Company's disclosure documents.
|SOURCE INTER CANADIAN BUSINESS SERVICE|
Copyright©2009 PR Newswire.
All rights reserved